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Abstract
Previous studies have shown that TSPO as well as apolipoprotein E (Apo E) can be
associated with processes such as cholesterol metabolism, oxidative stress, apopto‐
sis, glial activation, inflammation, and immune responses. As a ligand for cell-sur‐
face lipoprotein receptors, apolipoprotein E can prevent atherosclerosis by clearing
cholesterol-rich lipoproteins from plasma. Furthermore, TSPO takes part in the reg‐
ulation of gene expression for proteins involved in adhesion, which potentially may
play a role in platelet aggregation. There are indications that the Apo E protein is
involve in platelet aggregation, while TSPO platelet levels have been found to be in‐
creased with various neurological disorders, in particular, in stress-related disor‐
ders. The role of platelets in atherogenesis and the potential therapeutic impact of
TSPO ligands on disease prevention are of great interest. To determine TSPO bind‐
ing characteristics in this paradigm, we applied binding assays with [3H]PK 11195
on isolated platelets and erythrocyte membranes. The in vivo findings in Apo E
knockout mice revealed that TSPO levels appear to be enhanced in platelets and er‐
ythrocytes of Apo E knockout mice, and thus suggest that TSPO and Apo E expres‐
sion may be interconnected in relation to some aspect of the host defense response.
Other organs tested, such as liver, testis, brain, heart, aorta, lung, kidney and
spleen, did not show a difference in TSPO binding levels between Apo E knockout
mice and wild-type mice. This suggests that TSPO levels may be part of a feedback
control system for steroid production (responding to alterations in steroid levels),
rather than being regulated by a feed-forward signal provided by cholesterol (i.e.
TSPO levels in relation to steroidogenesis are not being regulated by cholesterol lev‐
els in vivo).
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1. Introduction
1.1. The connection of apolipopoprotein E and platelet activation to inflammation and
atherosclerosis
Atherosclerosis is a chronic inflammatory disease of the arteries of multifactorial etiology that
involves a complex interaction among oxidized lipids, plasma proteins, vascular endothelial
and smooth muscle cells and platelets [1–3]. Hypercholesterolemia and especially high
concentrations of low-density lipoproteins (LDL) are significant factors for the premature
development of atherosclerotic plaque. In parallel, elevated LDL levels exert prothrombotic
effects via platelet activation [4].
Dysfunction or low levels of platelets predispose to bleeding, while high levels, although
usually asymptomatic, may increase the risk of thrombosis, thus relating to atherosclerosis
and Apo E malfunction [5]. Studies from Kolodgie et al. demonstrated that platelets and
erythrocytes can penetrate the plaque through angiogenic capillary breakages [6]. Further‐
more, platelets with their pro-atherogenic potential are regarded as discrete immune cells [7,
8]. They can accumulate lipids in the hypercholesterolemic environment and are involved in
the early phase of atheromatous formation [9]. Oxidized low-density lipoproteins (ox-LDLs)
are suggested to be implicated in the early phase of atherosclerosis by recruiting inflammatory
cells in the subendothelium that elucidate the thrombotic process [10]. Several cells including
endothelial cells, macrophages and smooth muscle cells determine ox-LDL formation. In
vitro studies have shown that ox-LDL binds to platelets via CD36 and lectin-like endothelial
receptor for ox-LDL (LOX-1 receptors), promoting platelet activation [11, 12]. Experimental
studies demonstrated a marked reduction of thrombus formation in animals with the deletion
of ox-LDL receptor CD36 from platelets [13]. In accordance with a number of in vitro results,
in vivo LOX-1 expression, was not only upregulated under the influence of proinflammatory
stimulus but also induced in adipose tissue after high-fat diet feeding, suggesting that
increased LOX-1 expression may promote atherosclerosis [14, 15].
Apolipoprotein E functions as an important carrier protein in the redistribution of lipids
among cells, by incorporating into high-density lipoproteins (as HDL-E), and plays a promi‐
nent role in the transport (by incorporating into intestinally synthesized chylomicrons) and
metabolism of plasma cholesterol and triglyceride through its ability to interact with the LDLR
and the receptor binding of Apo E lipoproteins (apoER) [16, 17]. The metabolic activity of Apo
E is sensitive to its lipid environment; purified Apo E does not interact with the LDLR [18].
Apo E at the surfaces of VLDL and chylomicrons is also inactive unless these lipoproteins are
from hypertriglyceridemic subjects [19] or have undergone substantial lipolysis to form
remnant particles [20]. Apo E is part of different metabolic pathways in the body. One of these
pathways is endocrine-like, and involves the redistribution of lipids among cells of different
organs. It takes lipids from the areas where the lipid is synthesized and distributes them to
other areas where the lipids are used or stored. Another pathway is paracrine-like, where the
lipids are transported among cells in the same organ or tissue. Since Apo E is involved directly
in the uptake and distribution of plasma lipids, it is natural that it has several implications for
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cardiovascular disease. Interestingly, oxLDL as a ligand for LOX-1 is highly present in
circulation and lesion formation in atherosclerotic prone animals, such as Apo E KO mice.
The Apo E is also involved in various pathways that are unrelated to lipid transport, such as
the stimulation of lymphocytes and macrophage secretion [21]. This appears important for
facilitating local cholesterol redistribution and for reverse cholesterol transport [22]. As a
ligand for cell surface lipoprotein receptors, apolipoprotein E can prevent atherosclerosis by
clearing cholesterol-rich lipoproteins from plasma. Indeed, atherosclerosis in Apo E-deficient
(Apo E2/2) mice can be prevented by transplantation of normal murine bone marrow cells [23],
by macrophage-specific expression of the human Apo E transgene [24], or by adenovirus-
mediated gene replacement [25]. It was also found that altered Apo E expression leads to
enhanced inflammation responses [26–28].
Defects in Apo E sometimes result in its inability to bind to the LDL receptors, which leads to
an increase in a person's blood cholesterol. Recently, it has been suggested that high cholesterol
levels due to Apo E malfunction may constitute a risk factor for Alzheimer’s disease [29, 30].
According to the expressed isoforms, Apo E might be involved (i) in maintaining the integrity
of the aging CNS [31]; (ii) in repair, growth and maintenance of myelin and axonal membranes
during development and after an injury [32]; (iii) in neurite outgrowth [33]; (iv) in neurotoxicity
[34]; and (v) in pathological processes in general, including Alzheimer's disease [35].
Riddell’s study found that HDL-E was a powerful inhibitor of agonist-induced platelet
aggregation, through interaction with saturable binding sites in the platelet surface membrane,
which further suggested that Apo E exerts its antiplatelet aggregation effect via L-arginine:
nitric oxide pathway by enhancing the production of endogenous nitric oxide (NO) [36].
Calcium is central to the control of platelet reactivity, interacting with diverse second mes‐
sengers through a myriad of complex but tightly regulated, signalling pathways [37]. Two
important control elements for suppression of platelet activation are the cyclic nucleotides,
cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and
agents that increase their intraplatelet levels exert antiaggregatory effects both in vitro and in
vivo [38]. Although Apo E induced increases in both cAMP and cGMP, additional experiments
implicated a specific stimulation of guanylate cyclase activity and a rise in cGMP as prereq‐
uisites for the antiplatelet action of Apo E. Using the L-arginine:nitric oxide pathway, the
vascular endothelium synthesizes NO from the terminal guanidine nitrogen atoms of L-
arginine using a soluble enzyme called NO synthase (NOS). NO then binds to soluble
guanylate cyclase to produce cGMP, which has inhibitory effects on platelet aggregation. The
increased levels of cGMP also decrease the amount of cAMP phosphodiesterase, the enzyme
that converts cAMP to AMP. The decrease in cAMP phosphodiesterase causes an increase in
cAMP, and cAMP also has an inhibitory effect on platelet aggregation [10, 36].
1.2. Potential functional commonalities between apolipoprotein E and 18 kDa translocator
protein
It was shown previously that the 18 kDa translocator protein (TSPO) is present throughout the
cardiovascular system and may be involved in cardiovascular disorders such as ischemia [36].
At cellular levels, TSPO is present in virtually all of the cells of the cardiovascular system,
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where they appear to take part in the responses to various challenges that an organism and its
cardiovascular system face, including atherosclerosis and accompanying symptoms [22, 39–
42].
The TSPO was previously known as peripheral type benzodiazepine receptor (PBR), since it
is capable of binding benzodiazepines and is found in most if not all peripheral tissues [43].
Mitochondrial membranes form the primary location for TSPO [44]. It is an integral membrane
protein that interacts with a wide variety of endogenous ligands, such as cholesterol and
porphyrins, and is also a target for several small molecules with substantial in vivo efficacy.
When complexed with the TSPO-specific radioligand PK11195, TSPO folds into a rigid five-
helix bundle.
TSPO are present in platelets, lymphocytes and mononuclear cells and are also found in the
endothelium, the striated cardiac muscle, the vascular smooth muscles and the mast cells of
the cardiovascular system. As TSPO is known to regulate heme metabolism, TSPO may play
essential roles in erythrocyte function [45]. TSPO in the cardiovascular system also appears to
play roles in several aspects of the immune response, such as phagocytosis and the secretion
of interleukin-2, interleukin-3 and immunoglobulin A [46]. Mast cells are considered to be
important for immune response to pathogens [47], and they have also been implicated in the
regulation of thrombosis and inflammation and cardiovascular disease processes such as
atherosclerosis as well as in neoplastic conditions [48]. Benzodiazepines have been found to
bind to specific receptors on macrophages and to modulate in vitro their metabolic oxidative
responsiveness [49]. Haemin, isolated from human erythrocytes, competitively inhibits
mitochondrial benzodiazepine binding with a Ki of 41 nM [50]. The TSPO might present a
therapeutic target for arrhythmia, myocardial infarction and cardiac hypertrophy by reducing
ROS. For example, the suppression of TSPO can prevent caspase cascade activation and
cytochrome c release, thus inhibiting ROS overload [5, 51–60]. The results from several in
vitro studies have implicated TSPO in cholesterol transport into mitochondria, the late-limiting
step in the steroid biosynthesis. Therefore, TSPO has been considered as a critical factor in
steroidogenesis. Moreover, the ubiquitous expression and evolutionary conservation of TSPO
from bacteria to mammals strongly suggested its essential role in cellular processes. This
presumption was further supported by the results of an earlier study that claimed the
embryonic lethality of TSPO whole-body knockout (KO) mice, although the details of the
methods for the design and generation of the KO mice were not provided [52, 53].
A scheme of the involvement of mitochondrial TSPO in various cellular functions and disease
is given in Figure 1. For detailed discussions regarding these functional pathways, see refs. [49]
and [58].
TSPO molecules are often found in groups and in conjugation with VDAC and ANT. As
indicated in the figure, pk10, PRAX-1 and PAP7 face the cytosol. Furthermore, molecules of
the Bcl-2 family and creatine kinase and hexokinase can be attached to VDAC and ANT.
Various synthetic ligands that bind to TSPO have been developed. Endogenous ligands that
bind to TSPO include: protoporphyrin IX, DBI and its fragment TTN and PLA2. The TSPO is
involved in various functions as indicated towards the bottom of the figure. Abbreviations:
ANT, adenine nucleotide transporter; ATP, adenosine triphosphate; DBI, diazepam-binding
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inhibitor; PAP7, PBR-associated protein 7; PBR, peripheral-type benzodiazepine receptor;
pk10, protein of 10 kilodalton; PLA2, phospholipase A2; PRAX-1, PBR-associated protein 1;
TSPO, translocator protein (18 kDa); TTN, triakontatetraneuropeptide; VDAC, voltage-
dependent anion channel.
Recently, it was shown that TSPO ligands specifically designed for this purpose can increase
lifespan in animal models for human disease [61]. For example, the occurrence of cardiac arrest,
the typical cause of death in R6-2 mice, is delayed considerably in this animal model for
Huntington disease [62]. In numbers, average lifespan is increased from ±12 weeks to ±15
weeks. Translated to the human situation, this would mean in simple terms that life expectancy
of Huntington disease patients can potentially be increased from an average of 60 years to an
average of 85 years following treatments with the appropriate TSPO ligands. Such TSPO
ligands were also shown to prevent and counteract brain edema associated with seizures
developed after systemic injections of kainic acid in rats [61, 62].
Anti-inflammatory properties of TSPO ligands have also been demonstrated in nonneuronal
tissues [63]. TSPO ligands have been shown to reduce inflammation in animal models of
rheumatoid arthritis [59], carrageenan-induced pleurisy [64] and pulmonary inflammation
[65]. A summary of the involvement of TSPO and apoE in functions common to both as
suggested by previous studies discussed above is presented in Figure 2. Therefore, we studied
whether knockout of apolipoprotein E in mice may have an effect on TSPO expression in
platelets and erythrocytes. This could suggest that TSPO is involved in the regulation of
functions under the control of ApoE as mentioned in Figure 2.
Figure 1. The 18 kDa mitochondrial translocator protein (TSPO) in relation to cellular function and disease.
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Figure 2. Possible correlations between Apo E and TSPO due to potential participation in various functions.
2. Materials and methods
Apolipoprotein E–deficient mice (Apo E KO mice) present a well-established model to study
atherogenesis. In these mice, reverse cholesterol transport is dysfunctional, increasing the
blood cholesterol level up to five times higher than in normal mice [66]. As Apo E deficiency
causes increased cholesterol levels, which in turn may modulate TSPO function, we were
interested to study whether TSPO binding characteristics may be affected in erythrocyte and
platelet membranes. For this purpose, we used 12- to 14-week-old healthy male C57BL/6 mice
(i.e. wild type, WT) and 14-week-old Apo E knockout (KO) mice. The mice were housed in
polycarbonate cages in a pathogen-free facility set on a 12-h light–dark cycle and given ad
libitum access to water and standard laboratory feed. All experimental procedures were carried
out following the guidelines of the International European ethical standards for the care and
use of laboratory animals (Community Council Directive 86-609). All protocols were approved
and reviewed by the local ethics committee.
Platelets and erythrocytes preparation. Up to 1 mL of mouse blood was drawn by cardiac
puncture of deeply anesthetized fasting mice in a terminal procedure and collected in plastic
tubes containing trisodium citrate [3/8%, 1/10 (v:v)].
Platelet preparation
i. To obtain platelet-rich plasma (PRP), blood was centrifuged at 200×g for 20 min
ii. Then, 3/4 of the supernatant was collected to a new tube and centrifuged at 1000×g
for 30 min
iii. The pellet was washed with Tyrode’s buffer (Sigma-Aldrich, T1788) in a volume
identical to the volume of the original fluid and centrifuged at 1000×g for 15 min and
the pellet that contained only platelets was used for binding assay
Erythrocyte preparation
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i. The pellet obtained from the first centrifugation (protocol i) at 200×g, was washed
three times in isotonic solution of sodium chloride and used for isolation of erythro‐
cyte membranes
ii. Purified erythrocytes were suspended in a 30-fold volume of 20 mM PBS containing
1 mM MgCl2, pH 7.5, allowed to stand for one hour prior to centrifugation at
13,000×g, 40 min at 4°C, in order to obtain erythrocyte membrane as pellet [67]
iii. Protein concentration of membrane preparations were determined by the Bradford
assay [68, 69]
Assays of TSPO binding characteristics by [3H]PK 11195 binding measurements. Maximal
binding capacity (Bmax) and equilibrium dissociation constant (Kd) of the binding of the TSPO-
specific ligand, [3H]PK 11195, in whole cell membrane preparations from the platelets and
erythrocytes were assayed as described previously [40, 70, 71]. [3H]PK 11195 (1-(2-chlorphen‐
yl)-N-methyl-N-(1-methypropyl)-3-isoquinolinecarboxamide) was obtained from New
England Nuclear (Boston, MA). Unlabeled PK 11195 was purchased from Sigma-Aldrich,
Israel (Rehovot, Israel).
Procedure
• For binding assays of the Bmax and the Kd, the reaction mixtures contained 400 µL of the
membrane preparation in question (≈100 µg protein) and 25 µL of [3H]PK 11195 solution
(0.2 to 6 nM final concentrations) in the absence (total binding) or presence (nonspecific
binding) of 75 µL unlabeled PK 11195 (10 µM final concentration)
• After incubation for 90 min in ice-water bath, the samples were vacuum filtered through
Whatman GF/C filters, washed three times with 4 mL of 50 mM phosphate buffer and placed
in vials containing 4 mL of Opti-Fluor (Waltham, MA)
• Radioactivity was counted after 12 h with a 1600CA Tri-Carb liquid scintillation analyser
(Packard, Meriden, CT). Scatchard analysis of [3H]PK 11195 binding was done to determine
the Bmax and Kd values
• For one point binding analysis, the concentration of 6 nM [3H] PK 11195 was applied
The Bradford assay is based on the equilibrium between three forms of Coomassie blue G dye.
Under strong acidic conditions, the dye is stable as a doubly protonated red form. Upon
binding to protein, it is most stable as an unprotonated, blue form. Determination of microgram
quantities of protein in the Bradford Coomassie brilliant blue assay is established by meas‐
urement of absorbance at 590 nm [69]. For this protein assay, Bradford solution (comprising
Coomassie Brilliant Blue G-250 and an acid with a pKa of 1–2) was obtained from Bio-Rad
(Munich, Germany).
Procedure
• 10 µL from each sample was mixed with 200 µL of Bradford solution in 96-well plates, and
incubated for 10 min in the dark at room temperature
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• Absorption was measured using an ELISA Reader or “ULTRASPECTRO 2000” at 595 nm.
The protein concentration was determined by comparing the absorption values of the
protein samples to the appropriate BSA standard curve, prepared from the BSA volumes:
0, 2, 4, 8, 10, 15, 20, 25, 50, 100 and 150 µL, completed to a final volume of 800 µL by DDW
3. Results with discussion
Atherosclerosis is characterized by inflammatory infiltration into the arterial wall of macro‐
phages, dendritic cells, platelets and activated T cells, resulting in plaque formation. This
process is initiated by inappropriate lipid metabolism, calcium signaling and increased burden
of secretory pathways [3]. Macrophages, especially in the atherosclerotic plaque, contribute to
the local inflammatory responses by secreting proinflammatory cytokines [72]. Activated
macrophages have been demonstrated with high TSPO expression levels [73, 74]. TSPO has
been identified in human leukocytes and erythrocytes and appears to play roles in several
aspects of the immune response and the regulation of the host defense response in general [43,
46]. In addition, TSPO was detected in the plasma membrane of neutrophils, where it was
shown to stimulate adhesion and motility [75].
Apolipoprotein E may also be involved in the immune response, as suggested by the impaired
immune response in Apo E-deficient mice [76]. TSPO levels in platelets of rats and humans
have been demonstrated to respond to a wide variety of pathological conditions [46, 77, 78].
It has been suggested that TSPO density in platelets can be used as a promising biological
marker of stressful conditions [79–81].
To determine TSPO binding characteristics in Apo E-KO mice, we applied binding assays with
the TSPO-specific ligand [3H] PK 11195. Since cholesterol plays an important role in steroido‐
genesis, atherosclerosis and Alzheimer’s disease, which have been correlated with TSPO and
Apo E expression, we expected to find changes in TSPO binding levels in platelets and
erythrocytes of Apo E-knockout mice compared to their WT strain. Indeed, regarding the
platelets and erythrocytes, a significant increase (p < 0.05) in TSPO binding was noticed in Apo
E knockout mice compared to WT (Table 1). In addition, our results showed no major difference
in TSPO Bmax between WT and Apo E-KO mice in other tissues (data not shown); suggesting
that the effects seen on platelets and erythrocytes may be quite specific in relation to athero‐
sclerosis.
Scatchard analysis demonstrates [3H]PK 11195 binding of 1923 ± 1010 fmol/mg protein in
erythrocyte membranes of wild-type mice vs. 3142 ± 1761 fmol/mg measured in erythrocytes
membranes in the Apo E KO group (Figure 2). The obtained results from erythrocytes'
membranes in our study are in the range of those in human membranes as measured by Olson
et al. [67]. In these human erythrocytes, the Bmax was 1120 fmol/mg protein and the Kd 3.9 ± 0.4
nM. It has been suggested that TSPO present in the plasma membrane of erythrocytes is
involved in redistribution of intracellular cholesterol to change the nuclear membrane rigidity
prior to erythrocyte maturation [82]. Recent studies by us have shown that TSPO is involved
in the regulation of gene expression as well as heme metabolism [45, 83, 84]. More studies may
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provide deeper insights into how TSPO is involved in molecular biological mechanisms and
biological functions of erythrocytes.
Wild type mice Apo E KO mice
Cells B/ 6nM (fmoles/mg) Kd (nM) n B/ 6nM (fmoles/mg) Kd (nM) n
Platelets 1445 ± 736 0.8 ± 0.3 6 6201 ± 2681** 1.3 ± 0.5 6
Erythrocytes 1923 ± 1010 2.6 ± 0.8 7 3142 ± 1761* 4.2 ± 1.8 6
Table 1. [3H] PK 11195 binding parameters in mice erythrocyte and platelet membranes
Average B values fmoles/mg protein and Kd values (nM) of 6 nM [3H]PK 11195 binding to
TSPO in erythrocyte and platelets membranes of WT (Bb-Control) and Apo E KO mice, fed
with standard feed. One-way analysis of variance ANOVA was used, with Mann–Whitney as
the post hoc, nonparametric test. Data are expressed as mean ± SD; *, p < 0.05; **, p < 0.01, vs.
control.
Activated platelets are detected in increased numbers in the circulation of patients with
atherosclerosis, coronary artery disease, and hypercholesterolemia. In the advanced athero‐
sclerosis model of Apo E KO mice, subendothelial infiltration of monocytes/macrophages and
platelets was observed, suggesting intimate interactions of platelets and macrophages in early
atherosclerosis [85]. A recent paper by Nishikawa et al. demonstrated the role of hydrogen
sulfide (H2S), a gasotransmitter, in inhibiting platelet aggregation by interfering the cytosolic
Ca2+ mobilization in a cAMP-dependent manner, comparable to what is observed for nitric
oxide (NO) [86]. Studies by us have suggested that functions regulated by NO require the
presence and activation of TSPO [87]. A study from Hamilton et al. indicated that activation
of platelets with thrombin and other agents can promote atherogenesis [2]. Activation of
human platelets is inhibited by two intracellular pathways regulated by either cyclic AMP or
cyclic GMP. The importance of cyclic second messengers in modulating platelet reactivity is
well established, elaborating the lipid-lowering effects of simvastatin therapy on inhibition of
platelet aggregation through increasing the levels of both cAMP and cGMP [4]. Although Apo
E induced increases in both cAMP and cGMP, additional experiments implicated a specific
stimulation of guanylate cyclase activity and a rise in cGMP as prerequisites for the inhibitory
effects on platelet aggregation of Apo E. Nonetheless, the mechanisms by which platelets
promote atherogenesis need further observations.
Both TSPO and Apo E have been found to be involved in neurodegeneration. Both molecules
have been associated with particular common factors being part of neurodegenerative
diseases, such as cholesterol metabolism, oxidative stress, apoptosis and inflammation (Figure
1). Furthermore, Apo E was found to be involved in platelet aggregation, while TSPO expres‐
sion in platelets has been associated with various pathological conditions, including neuro‐
logical disorders [46]. Some authors have reported the protective effects of TSPO agonists in
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experimental neuropathy, suggesting reparative actions of brain TSPO in such a disease [88].
A recent study from Giannaccini et al. demonstrated upregulated TSPO expression in the brain
region of leptin-deficient obese mice (ob/ob) [89]. In addition, the induction of TSPO expression
under neuropathological conditions suggests that this molecule may be involved in the
response of the neural tissue to inflammation [90, 91]. Indeed, application of TSPO ligands can
dramatically decrease neuropathological symptoms of various diseases and injuries [61, 62].
However, the precise role of TSPO in the injured neural tissue needs to be investigated further.
In conclusion, the platelets' and erythrocytes' constant exposure to enhanced levels of choles‐
terol in the bloodstream may be associated with increased TSPO levels. One mechanism may
be that apoE's modulation of NO levels may affect TSPO expression in the platelets and
erythrocytes. Our study indicates that the Apo E mouse presents a promising animal model
to elucidate the exact role of TSPO in platelets and erythrocytes in a cholesterol-dependent
atherosclerosis. Thus, the TSPO represent a novel therapeutic target and diagnostic tool for
cardiovascular disease and its complications.
Explanation of abbreviations and symbols: ANOVA, analysis of variance; ApoE–/– KO,
apolipoprotein E knockout mice; ApoER, apolipoprotein E receptor; BSA, bovine serum
albumin; cAMP, adenosine 3,5-cyclic monophosphate; DBI, diazepam binding inhibitor; CAM,
cell adhesion molecule; Er, erythrocytes; H2S, hydrogen sulfide; HDL, high-density lipopro‐
tein; kDa, kilodalton; Kd, equilibrium dissociation constant; Km, equilibrium constant related
to Michaelis–Menten kinetics (similarly, Kd, Ka, Keq, Ks); LDL, low-density lipoproteins; LDLR,
low-density lipoprotein receptor; LOX-1, the lectin-like endothelial receptor for ox-LDL;
mPTP, mitochondrial permeability transition pore; MCP-1, monocyte chemoattractant
protein-1; NADP, nicotinamide adenine dinucleotide phosphate; NADH, reduced nicotina‐
mide adenine dinucleotide; NO, nitric oxide; NOS, nitric oxide synthase; ox-LDL, oxidized
low-density lipoproteins; PBR, peripheral-type benzodiazepine receptor; PK 11195, 1-(2-
   
A B 
Figure 3. Representative examples of Scatchard plots of saturation curves of [3H] PK 11195 binding to membrane prep‐
arations of platelets of wild-type mice (A) and apo E-KO mice (B). Abbreviations: B, bound; B/F, bound over free.
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chlorophenyl)-N-methyl-N-(1-methyl-prop1)-3 isoquinoline carboxamide; ROS, reactive
oxygen species; TSPO, 18 kDa translocator protein.
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